Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

567
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
567
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

902
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
902
Lipid Absorption01:24

Lipid Absorption

3.3K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.3K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

373
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
373
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-enabled GRADE: How the GRADE Working Group will use automation to rate the certainty of evidence of intervention effects.

Journal of clinical epidemiology·2026
Same author

Cochrane Evaluation of (Semi-) Automated Review Methods (CESAR): Protocol for an adaptive platform study within reviews.

Journal of clinical epidemiology·2026
Same author

Area under the likelihood curve as a measure of evidential weight in nonsignificant meta-analyses: a meta-epidemiological study.

Journal of clinical epidemiology·2026
Same author

Assessing the trustworthiness of health guidelines recommendations: the transparent, rigorous, useable, standardized, and trustworthy guide (TRUSTGUIDES) tools development.

Journal of clinical epidemiology·2026
Same author

Evaluating search approaches for a network meta-analysis: a case study of Epistemonikos Database of Trials, CENTRAL, and other sources.

BMC medical research methodology·2026
Same author

Evaluating evidential strength of statistically nonsignificant meta-analyses with likelihood ratios: a meta-epidemiological study.

Journal of clinical epidemiology·2026

Related Experiment Video

Updated: Mar 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Ezetimibe-Statin Combination Therapy.

Barbara Nußbaumer1, Anna Glechner, Angela Kaminski-Hartenthaler

  • 1Danube University Krems, Department for Evidence-based Medicine and Clinical Epidemiology, Krems an der Donau, Austria, Research Triangle Institute International, New York, USA.

Deutsches Arzteblatt International
|July 15, 2016
PubMed
Summary
This summary is machine-generated.

Ezetimibe-statin combination therapy significantly reduces cardiovascular events compared to statin monotherapy in high-risk patients. However, it does not impact overall mortality, with similar safety profiles observed between the two treatments.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Experiment Videos

Last Updated: Mar 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Most clinical trials compare ezetimibe-statin combination therapy vs. statin monotherapy using surrogate variables.
  • This systematic review focuses on preventing actual cardiovascular events in hyperlipidemic patients with atherosclerosis and/or diabetes mellitus.

Purpose of the Study:

  • To evaluate the efficacy and safety of ezetimibe-statin combination therapy versus statin monotherapy.
  • To assess the prevention of cardiovascular events in high-risk patient populations.

Main Methods:

  • Systematic literature search of PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov (1995-2015).
  • Inclusion of nine randomized, controlled trials with 19,461 patients.

Main Results:

  • Ezetimibe-statin combination therapy showed a lower risk of cardiovascular events (33% vs. 35%) over seven years (NNT: 50).
  • Combination therapy significantly reduced a composite endpoint of cardiovascular events (HR 0.94; p=0.016) and benefited diabetic patients (HR 0.87).
  • No significant difference in cardiovascular or overall mortality; similar rates of serious adverse events (RR 1.09).

Conclusions:

  • Ezetimibe-statin combination therapy lowers cardiovascular event risk versus statin monotherapy in high-risk patients, particularly those with acute coronary syndrome.
  • The combination therapy demonstrated similar safety and mortality risks compared to statin monotherapy.